Emphysema
Emphysema refers to a pathological state in which the airway elasticity of the distal end of the terminal bronchioles (respiratory bronchioles, alveolar ducts, alveolar sacs and alveoli) is reduced, over-expanded, inflated and the lung volume increases or is accompanied by airway wall destruction. According to the cause of the disease, there are several types of emphysema: senile emphysema, compensatory emphysema, interstitial emphysema, focal emphysema, paraseptal emphysema, and obstructive emphysema.
-
Site of disease:
lung -
Infectious :
Not contagious -
Frequent population:
Middle-aged and elderly people -
Related symptoms:
Cough Pulmonary dyspnea Cheek puffing and pursed lips during exhalation Lung hyperinflation Cyanosis -
Concurrent disease:
Related Drugs
ARFORMOTEROL TARTRATE- arformoterol tartrate_solution
Indication: Arformoterol tartrate inhalation solution is a long-acting beta 2 2 Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. 1 Important limitations of use: Arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. 2 Arformoterol tartrate inhalation solution is not indicated to treat asthma. 2 Arformoterol tartrate inhalation solution is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Arformoterol tartrate inhalation solution is for use by nebulization only. Arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [ see Warnings and Precautions(5. 2) Arformoterol tartrate inhalation solution is not indicated to treat asthma. The safety and effectiveness of arformoterol tartrate inhalation solution in asthma have not been established.
Manufacturer:
Ingenus Pharmaceuticals, LLC
FORMOTEROL FUMARATE- formoterol fumarate_solution
Indication: Formoterol fumarate inhalation solution is a long-acting beta 2 2 Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. 1 Important limitations of use: Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. 2 Formoterol fumarate inhalation solution is not indicated to treat asthma. 2 Formoterol fumarate inhalation solution is indicated for the long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see WARNINGS AND PRECAUTIONS 5. The safety and effectiveness of formoterol fumarate inhalation solution in asthma have not been established.
Manufacturer:
Ingenus Pharmaceuticals, LLC
THEOPHYLLINE_- theophylline_tablet, extended release
Indication: Theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
Manufacturer:
Ajanta Pharma USA Inc.
IPRATROPIUM BROMIDE- ipratropium bromide_solution
Indication: Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Manufacturer:
Proficient Rx LP